Item 8.01 Other Events.

On July 5, 2012, AspenBio Pharma, Inc. (the "Company") received correspondence from The NASDAQ Stock Market confirming that the Company had regained compliance with Listing Rule 5550(a)(2) that establishes the minimum closing bid price requirements for listed companies. On July 10, 2012, the Company issued a press release titled, "AspenBio Pharma Notified by NASDAQ that it Regained Compliance with All NASDAQ Capital Market Continued Listing Standards." A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits

99.1 Press Release of AspenBio Pharma, Inc. titled "AspenBio Pharma Notified by NASDAQ that it Regained Compliance with All NASDAQ Capital Market Continued Listing Standards," issued July 10, 2012.

---